跳至主要内容
临床试验/EUCTR2008-001184-11-DE
EUCTR2008-001184-11-DE进行中(未招募)不适用

Effect of prandial treatment with insulin VIAjectTM compared to regular human insulin and insulin lispro on postprandial endothelial function and microvascular stress in type 2 diabetic patients

Biodel Inc0 个研究点开始时间: 2008年3月3日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
Biodel Inc

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1. Type 2 diabetes mellitus according to the ADA criteria
  • 2. HbA1c between 6.5 % and 9.9 %
  • 3. Treatment with sulfonylurea and/or metformin in a stable dosage within the last 3 months
  • 4. Age between 40 and 75 years
  • 5. BMI < 40
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • 1. Type 1 diabetes mellitus
  • 2. Pre-treatment with insulin within the last 6 months prior to screening
  • 3. Pre-treatment with PPARy-agonists or glucosidase inhibitors within the last 4 weeks prior to screening
  • 4. Untreated hypertension stage II-III according to WHO criteria
  • 5. Planned or anticipated change in antidiabetic and/or concomitant medication during study participation
  • 6. Total cholesterol > 300 mg/dl (anamnestically)
  • 7. Major micro- or macrovascular complications as judged by the investigator
  • 8. Tobacco use within the last 6 months prior to screening
  • 9. Drugs with major impact on endothelial function like nitrates etc.
  • 10. History of drug or alcohol abuse which in the opinion of the investigator will impair subject safety or protocol compliance
  • 11. History of hypersensitivity to the study drugs or to drugs with similar chemical structures
  • 12. History of severe or multiple allergies
  • 13. Treatment with any other investigational drug within 3 months prior to screening
  • 14. Progressive fatal disease
  • 15. History of significant cardiovascular, respiratory, gastrointestinal, hepatic (ALAT and/or ASAT > 3 times the normal reference range), renal (creatinine > 1.1 mg/dL in women and > 1.5 mg/dL in men), neurological, psychiatric and/or haematological disease as judged by the investigator
  • 16. Pregnancy or breast feeding
  • 17. Sexually active women of childbearing potential not consistently and correctly practicing birth control by implants, injectables, oral contraceptives, hormonal intrauterine devices (IUDs), sexual abstinence or vasectomised partner
  • 18. Lack of compliance or other similar reasonthat at the discretion of the investigator precludes satisfactory participation in the study
  • 19. Hypopotassemia (K<3.5 mmol /l)

研究者

发起方
Biodel Inc

相似试验